The development of effective and safe treatments for osteoarthritis (OA), the most common chronic joint disease, is one of the main challenges facing modern medicine. Despite the fact that there are many drugs and non-drug therapies, the treatment of OA is not always successful, especially in terms of long-term prognosis. This is determined by the heterogeneity of OA, different phenotypes of this disease, as well as by a significant variability in its course, which complicates individual therapy choice. In this situation, a well-informed patient can become an effective physician assistant. Thus, the patient can control his/her condition in accordance with the responsible self-treatment principles: to assess therapy results and disease exacerbations, to maintain muscle tone and the necessary level of motor activity, to carry out therapeutic exercises, as well as to independently stop short-term increased pain episodes with over-the-counter analgesics. One of the most popular over-the-counter painkillers used worldwide is naproxen administered in low doses. This drug has proven to be an effective analgesic with good tolerability, standing out among all nonsteroidal anti-inflammatory drugs having a minimal risk for cardiovascular events. Teraliv 275 mg, a new over-thecounter formulation of naproxen, has currently emerged in Russia now. It seems that this medication will become an essential element of therapy for OA within the concept of responsible self-medication.